The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease

Mol Biol Rep. 2021 May;48(5):4789-4796. doi: 10.1007/s11033-021-06457-z. Epub 2021 Jun 1.

Abstract

Calcium Pyrophosphate Crystal Deposition (CPPD) disease is characterized by the deposition of calcium pyrophosphate crystals in the cartilage. In most cases, it can manifest as a subclinical condition named chondrocalcinosis, often revealed by joint x-ray examination. In other cases, deposition can cause flares of arthritis, known as acute CPP crystal arthritis. In the last few years, many pathogenic pathways have been discovered. Interleukin-1 (IL-1) plays a key role in the pathogenesis of CPPD disease, both as a mediator of inflammatory response to crystals and as a promoter of damage to articular cartilage. In this review, we investigated the role of IL-1R inhibitor, such as Anakinra, as an alternative to the various therapeutic strategies for CPPD disease, especially among patients resistant to traditional treatment with NSAIDs, corticosteroids and colchicine.

Keywords: Anakinra; Arthritis; CPPD; IL-1; Pseudogout.

Publication types

  • Review

MeSH terms

  • Arthritis / etiology
  • Chondrocalcinosis / drug therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Inflammation / drug therapy
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Interleukin-1 / metabolism
  • Receptors, Interleukin-1 / metabolism

Substances

  • Immunosuppressive Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Receptors, Interleukin-1